



Press release
April 4, 2018
Gothenburg

Annual Report 2017

Today XVIVO Perfusion is publishing the Annual Report for 2017 (in Swedish). The Annual Report is attached to this press release and will also be available on www.xvivoperfusion.com.

A printed version of the Annual Report 2017 can be ordered by phone +46 (0)31 788 21 50 or by email info@xivoperfusion.com.

April 4, 2018
Gothenburg
XVIVO Perfusion AB (publ)

For further information, please contact
Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 21 50, magnus.nilsson@xivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ First North Premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.

Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.

E-mail: info@xivoperfusion.com. Website: www.xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on April 4, 2017 at 12:00 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.